image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 96.31
-2.08 %
$ 244 B
Market Cap
20.15
P/E
1. INTRINSIC VALUE

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.[ Read More ]

The intrinsic value of one MRK stock under the base case scenario is HIDDEN Compared to the current market price of 96.3 USD, Merck & Co., Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart MRK

image
FINANCIALS
60.1 B REVENUE
1.40%
2.95 B OPERATING INCOME
-84.77%
365 M NET INCOME
-97.49%
13 B OPERATING CASH FLOW
-31.89%
-14.1 B INVESTING CASH FLOW
-183.93%
-4.81 B FINANCING CASH FLOW
47.25%
16.7 B REVENUE
3.10%
4.91 B OPERATING INCOME
-21.63%
3.17 B NET INCOME
-41.85%
9.29 B OPERATING CASH FLOW
64.82%
-3.84 B INVESTING CASH FLOW
-259.68%
-2.42 B FINANCING CASH FLOW
-199.42%
Balance Sheet Decomposition Merck & Co., Inc.
image
Current Assets 32.2 B
Cash & Short-Term Investments 7.09 B
Receivables 11.7 B
Other Current Assets 13.4 B
Non-Current Assets 74.5 B
Long-Term Investments 1.56 B
PP&E 24.5 B
Other Non-Current Assets 48.5 B
Current Liabilities 25.7 B
Accounts Payable 3.92 B
Short-Term Debt 1.37 B
Other Current Liabilities 20.4 B
Non-Current Liabilities 43.3 B
Long-Term Debt 34.6 B
Other Non-Current Liabilities 8.74 B
EFFICIENCY
Earnings Waterfall Merck & Co., Inc.
image
Revenue 60.1 B
Cost Of Revenue 16.1 B
Gross Profit 44 B
Operating Expenses 44 B
Operating Income 2.95 B
Other Expenses 2.59 B
Net Income 365 M
RATIOS
73.17% GROSS MARGIN
73.17%
4.91% OPERATING MARGIN
4.91%
0.61% NET MARGIN
0.61%
0.97% ROE
0.97%
0.34% ROA
0.34%
0.81% ROIC
0.81%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Merck & Co., Inc.
image
Net Income 365 M
Depreciation & Amortization 3.87 B
Capital Expenditures -3.86 B
Stock-Based Compensation 645 M
Change in Working Capital -2.2 B
Others 12.4 B
Free Cash Flow 9.14 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Merck & Co., Inc.
image
Wall Street analysts predict an average 1-year price target for MRK of $141 , with forecasts ranging from a low of $132 to a high of $148 .
MRK Lowest Price Target Wall Street Target
132 USD 37.06%
MRK Average Price Target Wall Street Target
141 USD 46.64%
MRK Highest Price Target Wall Street Target
148 USD 53.67%
4. DIVIDEND ANALYSIS
0.68% DIVIDEND YIELD
0.77 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Merck & Co., Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
34.5 M USD 3
9-12 MONTHS
17.1 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
9 months ago
Feb 14, 2024
Sell 4.81 M USD
Litchfield Caroline
EVP & CFO
- 38291
125.5 USD
9 months ago
Feb 13, 2024
Sell 15.7 M USD
Davis Robert M
Chairman, CEO & President
- 124676
125.7431 USD
9 months ago
Feb 14, 2024
Sell 10.7 M USD
Davis Robert M
Chairman, CEO & President
- 85021
125.3993 USD
9 months ago
Feb 13, 2024
Sell 3.2 M USD
Davis Robert M
Chairman, CEO & President
- 25324
126.3733 USD
9 months ago
Feb 13, 2024
Sell 125 K USD
Romanelli Joseph
President, Human Health Int?l
- 1000
124.8879 USD
9 months ago
Feb 09, 2024
Sell 1.85 M USD
Li Dean Y
Executive VP & President, MRL
- 14702
125.4988 USD
9 months ago
Feb 07, 2024
Sell 185 K USD
Williams David Michael
EVP,Chief Info&Digital Officer
- 1451
127.5729 USD
9 months ago
Feb 02, 2024
Sell 2.41 M USD
Oosthuizen Johannes Jacobus
President, U.S. Market
- 18959
127.175 USD
9 months ago
Feb 02, 2024
Sell 6.42 M USD
MIZELL STEVEN
EVP, Chief HR Officer
- 50694
126.6491 USD
9 months ago
Feb 02, 2024
Sell 6.28 M USD
Zachary Jennifer
EVP, General Counsel
- 49499
126.9678 USD
1 year ago
Nov 09, 2023
Sell 213 K USD
Oosthuizen Johannes Jacobus
President, U.S. Market
- 2081
102.3841 USD
1 year ago
Nov 08, 2023
Sell 4.6 M USD
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth
- 43823
105.0286 USD
1 year ago
Aug 14, 2023
Sell 463 K USD
MIZELL STEVEN
EVP, Chief HR Officer
- 4250
109.01 USD
1 year ago
Aug 03, 2023
Sell 475 K USD
MIZELL STEVEN
EVP, Chief HR Officer
- 4500
105.4891 USD
1 year ago
Aug 02, 2023
Sell 3.22 K USD
Romanelli Joseph
President, Human Health Int?l
- 30
107.371 USD
1 year ago
Aug 02, 2023
Sell 6.33 K USD
Romanelli Joseph
President, Human Health Int?l
- 59
107.371 USD
1 year ago
Mar 20, 2023
Bought 14.3 K USD
Romanelli Joseph
President, Human Health Int?l
+ 136
105.47 USD
1 year ago
Apr 26, 2023
Bought 341 USD
Romanelli Joseph
President, Human Health Int?l
+ 3
113.68 USD
1 year ago
Mar 24, 2023
Sell 3.66 K USD
Romanelli Joseph
President, Human Health Int?l
- 35
104.65 USD
1 year ago
Feb 21, 2023
Bought 1.2 K USD
Romanelli Joseph
President, Human Health Int?l
+ 11
109.2 USD
1 year ago
Dec 19, 2022
Bought 763 USD
Romanelli Joseph
President, Human Health Int?l
+ 7
109.04 USD
1 year ago
Dec 13, 2022
Bought 6.21 K USD
Romanelli Joseph
President, Human Health Int?l
+ 56
110.96 USD
1 year ago
Dec 06, 2022
Bought 3.28 K USD
Romanelli Joseph
President, Human Health Int?l
+ 30
109.39 USD
1 year ago
Dec 05, 2022
Bought 11.7 K USD
Romanelli Joseph
President, Human Health Int?l
+ 107
109.54 USD
1 year ago
Dec 02, 2022
Bought 6.47 K USD
Romanelli Joseph
President, Human Health Int?l
+ 59
109.67 USD
1 year ago
May 03, 2023
Sell 1.55 M USD
MIZELL STEVEN
EVP, Chief HR Officer
- 13000
119.0086 USD
1 year ago
May 03, 2023
Sell 1.79 M USD
MIZELL STEVEN
EVP, Chief HR Officer
- 15000
119.0081 USD
1 year ago
May 03, 2023
Sell 1.43 M USD
MIZELL STEVEN
EVP, Chief HR Officer
- 12000
119.0074 USD
1 year ago
May 03, 2023
Sell 1.59 M USD
MIZELL STEVEN
EVP, Chief HR Officer
- 13400
119.01 USD
1 year ago
May 04, 2023
Sell 2.25 M USD
Zachary Jennifer
EVP, General Counsel
- 19141
117.5923 USD
1 year ago
May 04, 2023
Sell 1.87 M USD
Karachun Rita A
Sr. VP Fince-Global Controller
- 15875
117.5334 USD
1 year ago
May 02, 2023
Sell 877 K USD
Williams David Michael
EVP,Chief Info&Digital Officer
- 7509
116.8228 USD
1 year ago
May 01, 2023
Sell 8.75 M USD
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth
- 75436
116.0288 USD
1 year ago
Apr 28, 2023
Sell 7.61 M USD
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth
- 66163
115.0015 USD
1 year ago
Apr 28, 2023
Sell 16.5 M USD
Davis Robert M
Chairman, CEO & President
- 143329
114.9303 USD
1 year ago
Apr 13, 2023
Sell 7.61 M USD
Chattopadhyay Sanat
Exe V-P & Pres. MMD
- 66163
115.0598 USD
1 year ago
Apr 13, 2023
Sell 7.81 M USD
Chattopadhyay Sanat
Exe V-P & Pres. MMD
- 67892
115.0705 USD
1 year ago
Feb 15, 2023
Sell 541 K USD
Romanelli Joseph
President, Human Health Int?l
- 5000
108.2201 USD
1 year ago
Feb 13, 2023
Sell 198 K USD
MIZELL STEVEN
EVP, Chief HR Officer
- 1815
109.1003 USD
1 year ago
Feb 09, 2023
Sell 535 K USD
MIZELL STEVEN
EVP, Chief HR Officer
- 5000
107.0013 USD
1 year ago
Feb 06, 2023
Sell 462 K USD
MIZELL STEVEN
EVP, Chief HR Officer
- 4436
104.2546 USD
1 year ago
Feb 03, 2023
Sell 7.78 M USD
Zachary Jennifer
EVP, General Counsel
- 75436
103.1704 USD
1 year ago
Jan 09, 2023
Sell 3.94 M USD
Chattopadhyay Sanat
Exe V-P & Pres. MMD
- 35598
110.6146 USD
1 year ago
Jan 09, 2023
Sell 507 K USD
Chattopadhyay Sanat
Exe V-P & Pres. MMD
- 4538
111.7339 USD
1 year ago
Jan 09, 2023
Sell 444 K USD
Chattopadhyay Sanat
Exe V-P & Pres. MMD
- 3940
112.7823 USD
1 year ago
Jan 09, 2023
Sell 4.35 M USD
Chattopadhyay Sanat
Exe V-P & Pres. MMD
- 38216
113.7752 USD
1 year ago
Jan 09, 2023
Sell 195 K USD
Chattopadhyay Sanat
Exe V-P & Pres. MMD
- 1702
114.4612 USD
2 years ago
Nov 08, 2022
Sell 2.02 M USD
MIZELL STEVEN
EVP, Chief HR Officer
- 20000
101 USD
2 years ago
Nov 10, 2022
Sell 1.52 M USD
MIZELL STEVEN
EVP, Chief HR Officer
- 15000
101.4185 USD
2 years ago
Nov 09, 2022
Sell 185 K USD
Oosthuizen Johannes Jacobus
President, U.S. Market
- 1795
103.21 USD
2 years ago
Nov 09, 2022
Sell 8.93 M USD
Davis Robert M
CEO & President
- 87595
101.9414 USD
2 years ago
Nov 09, 2022
Sell 8.23 M USD
Davis Robert M
CEO & President
- 79918
102.9796 USD
2 years ago
Nov 09, 2022
Sell 10.4 K USD
Davis Robert M
CEO & President
- 100
103.59 USD
2 years ago
Nov 07, 2022
Sell 2.45 M USD
FRAZIER KENNETH C
Executive Chair
- 24914
98.4539 USD
2 years ago
Nov 07, 2022
Sell 12.5 M USD
FRAZIER KENNETH C
Executive Chair
- 126134
99.4247 USD
2 years ago
Nov 07, 2022
Sell 8.48 M USD
FRAZIER KENNETH C
Executive Chair
- 84721
100.0663 USD
2 years ago
Nov 07, 2022
Sell 4.53 M USD
Oosthuizen Johannes Jacobus
President, U.S. Market
- 45561
99.4706 USD
2 years ago
Nov 04, 2022
Sell 19.7 M USD
FRAZIER KENNETH C
Executive Chair
- 200190
98.5326 USD
2 years ago
Nov 03, 2022
Sell 21.2 M USD
FRAZIER KENNETH C
Executive Chair
- 214617
98.6785 USD
2 years ago
Nov 04, 2022
Sell 3.45 M USD
FRAZIER KENNETH C
Executive Chair
- 34810
99.0804 USD
2 years ago
Nov 03, 2022
Sell 2.02 M USD
FRAZIER KENNETH C
Executive Chair
- 20383
99.0926 USD
2 years ago
Nov 01, 2022
Sell 20.2 M USD
FRAZIER KENNETH C
Executive Chair
- 202319
99.6065 USD
2 years ago
Nov 02, 2022
Sell 20.5 M USD
FRAZIER KENNETH C
Executive Chair
- 205661
99.6791 USD
2 years ago
Nov 01, 2022
Sell 9.72 M USD
FRAZIER KENNETH C
Executive Chair
- 96981
100.2242 USD
2 years ago
Nov 01, 2022
Sell 70.7 K USD
FRAZIER KENNETH C
Executive Chair
- 700
101.0471 USD
2 years ago
Nov 02, 2022
Sell 9.47 M USD
FRAZIER KENNETH C
Executive Chair
- 94339
100.4011 USD
2 years ago
Oct 28, 2022
Sell 10 M USD
Chattopadhyay Sanat
Exe V-P & Pres. MMD
- 100292
100.1015 USD
2 years ago
Oct 28, 2022
Sell 16.5 M USD
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth
- 164557
100.2637 USD
2 years ago
Oct 28, 2022
Sell 7.48 M USD
FRAZIER KENNETH C
Executive Chair
- 75489
99.1516 USD
2 years ago
Oct 31, 2022
Sell 7.06 M USD
FRAZIER KENNETH C
Executive Chair
- 70698
99.8157 USD
2 years ago
Oct 28, 2022
Sell 31.4 M USD
FRAZIER KENNETH C
Executive Chair
- 313232
100.2539 USD
2 years ago
Oct 31, 2022
Sell 23.2 M USD
FRAZIER KENNETH C
Executive Chair
- 229302
101.0341 USD
2 years ago
Oct 28, 2022
Sell 18 M USD
FRAZIER KENNETH C
Executive Chair
- 178363
100.7983 USD
2 years ago
Oct 28, 2022
Sell 3.21 M USD
Karachun Rita A
Sr. VP Fince-Global Controller
- 31997
100.3433 USD
2 years ago
Oct 28, 2022
Sell 1.7 M USD
MIZELL STEVEN
EVP, Chief HR Officer
- 17000
100 USD
2 years ago
Oct 28, 2022
Sell 791 K USD
MIZELL STEVEN
EVP, Chief HR Officer
- 8000
98.84 USD
2 years ago
Oct 28, 2022
Sell 364 K USD
Oosthuizen Johannes Jacobus
President, U.S. Market
- 3633
100.2105 USD
2 years ago
Oct 28, 2022
Sell 9.88 M USD
Zachary Jennifer
EVP, General Counsel
- 99768
99.07 USD
2 years ago
Oct 28, 2022
Sell 6.54 M USD
Zachary Jennifer
EVP, General Counsel
- 65487
99.85 USD
3 years ago
Nov 09, 2021
Sell 52.1 M USD
FRAZIER KENNETH C
Executive Chair
- 634266
82.2155 USD
3 years ago
Nov 09, 2021
Sell 2.46 M USD
FRAZIER KENNETH C
Executive Chair
- 29615
83.2303 USD
3 years ago
Nov 04, 2021
Sell 2.69 M USD
DeLuca Richard R.
EVP&Pres, Merck Animal Heallth
- 29782
90.4002 USD
7. News
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr. Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services. forbes.com - 1 day ago
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study. zacks.com - 1 day ago
European And US Vaccine Stocks Are Under Pressure - Here's WHy Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services. benzinga.com - 1 day ago
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM) RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma (MPM). “The. businesswire.com - 2 days ago
100 November Sustainable Dividend Dogs: 50 'Safer' And 2 Ideal Buys Calvert Research and Management ranked the 100 most sustainable companies based on over 230 ESG indicators, including workplace diversity and greenhouse-gas emissions. Eight of 78 dividend-paying sustainable companies offer dividends exceeding their share prices, signalling potential buy opportunities for investors. Analysts estimate net gains of 17.47% to 69.69% for the top ten sustainable companies by November 2025, based on target prices and dividends. seekingalpha.com - 2 days ago
Merck: Keytruda's Sales Projections Outweigh Competitive And Patent Risks Merck's stock is undervalued, trading at less than 4x expected 2024 revenues, despite strong revenue growth from Keytruda and other drugs. Keytruda's revenue is projected to increase by 70% from 2024 to 2032. Declining Gardasil sales in China and competition from Summit Therapeutics and Roche's Tecentriq may have contributed to recent stock volatility. seekingalpha.com - 3 days ago
Merck to Participate in the Jefferies London Healthcare Conference RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies London Healthcare Conference. businesswire.com - 3 days ago
Merck signs $3.3 bln deal for experimental cancer drug Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. reuters.com - 3 days ago
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. “At Merck, we continue to assemble a strong and diversified oncology pipeline spanning differentiated mechanisms an. businesswire.com - 3 days ago
Merck & Co., Inc. (MRK) UBS Global Healthcare Conference (Transcript) Merck & Co., Inc. (NYSE:MRK ) UBS Global Healthcare Conference November 13, 2024 12:30 PM ET Company Participants Jannie Oosthuizen - President of Human Health of the U.S. Joerg Koglin - SVP of Clinical Research Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think we're at time here. seekingalpha.com - 3 days ago
KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Plexiform Neurofibromas in Global Phase 3 KOMET Trial RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KOSELUGO Showed Significant and Clinically Meaningful Improvement in ORR Versus Placebo in Adults With NF1 who Have Symptomatic, Inoperable PNs. businesswire.com - 5 days ago
8. Profile Summary

Merck & Co., Inc. MRK

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 244 B
Dividend Yield 0.68%
Description Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Contact 2000 Galloping Hill Road, Kenilworth, NJ, 07033 https://www.merck.com
IPO Date Jan. 13, 1978
Employees 70000
Officers Ms. Betty D. Larson Executive Vice President & Chief Human Resources Officer Ms. Caroline Litchfield Executive Vice President & Chief Financial Officer Mr. David Michael Williams Executive Vice President and Chief Information & Digital Officer Mr. Sanat Chattopadhyay Executive Vice President & President of Merck Manufacturing Division Mr. Richard R. DeLuca Jr. Executive Vice President & President of Merck Animal Health Mr. Peter Dannenbaum Vice President of Investor Relations Ms. Cristal N. Downing Executive Vice President and Chief Communications & Public Affairs Officer Mr. Robert M. Davis J.D. Chairman, President & Chief Executive Officer Dr. Dean Y. Li M.D., Ph.D. Executive Vice President & President of Merck Research Laboratories Mr. Dalton E. Smart III Senior Vice President of Finance, Principal Accounting Officer & Global Controller